Última actualización :
19/11/2024
fármacos contra el cáncer   Carmustine  
Inyectables
Estabilidad en solucion Estabilidad en mezcla Factores que influyen sobre la estabilidad Compatibilidades método de inyección Bibliografía pdf
   Estructura química  

Nombre comercial   Nombre comercial     

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Becenun Brasil
Bicnu Australia, Canadá, Chile, Colombia, España, Estados Unidos de América, Francia, Gran Bretaña, Grecia, Hungría, Irán, Irlanda, Marruecos, Marruecos, México, Nueva Zelanda, Rumania, Suiza, Túnez
Bodacler Argentina
Carmubris Alemania, Austria, Irán
Carmustina Grey Marruecos
Carmustina Perulab Marruecos
Carmustine Baxter Nueva Zelanda
Carmustine Obvius Alemania, Austria, Bélgica, Bulgaria, Croacia, Dinamarca, Eslovaquia, Eslovenia, España, Finlandia, Francia, Gran Bretaña, Hungría, Irlanda, Islandia, Luxemburgo, Noruega, Países Bajos, Polonia, Portugal, República Checa, Rumania, Suecia
Nitrourean España
Nitrumon Bélgica, Irán, Luxemburgo
Bibliografía   Inyectables   Bibliografía : Carmustine  
Tipo Publicación
3 periódico Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81 periódico Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 periódico Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 periódico Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
146 periódico Hadji-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M.
Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine.
Clin Ther 1992 ; 14: 821-824.
169 periódico Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 periódico Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60.
244 periódico Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 periódico Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307 periódico Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 periódico Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 periódico Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
492 periódico Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
715 periódico Colvin M, Hartner J, Summerfield M.
Stability of carmustine in the presence of sodium bicarbonate.
Am J Hosp Pharm 1980 ; 37: 677-678.
837 periódico Fredriksson K, Lundgren P, Landersjo L.
Stability of carmustine - kinetics and compatibility during administration.
Acta Pharm Suec 1986 ; 23: 115-124.
905 periódico Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1410 periódico Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1423 periódico Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518.
1501 periódico Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1520 Laboratorio Etude de stabilité des médicaments en Ecoflac®
B Braun 2001
1622 periódico Favier M, De Casanove F, Coste A, Cherti N, Bressolle F.
Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers.
Am J Health-Syst Pharm 2001 ; 58: 238-241.
2146 periódico Trissel LA, Xu QA, Baker M.
Drug compatibility with new polyolefin infusion solution containers.
Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
3314 Laboratorio Carmustine (Bicnu®) – Résumé des caractéristiques du produits
Bristol Myers Squibb 2011
4762 periódico Knoll L, Kraemer I, Thiesen J.
Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature
EJHP 2023 ; 30, 1: 11-16.

  Mentions Légales